all report title image
  • Published In : Jun 2024
  • Code : CMI7096
  • Pages :160
  • Formats :
      Excel and PDF
  • Industry : Medical Devices

Market Size and Trends

The Global Life Science Instrumentation Market is estimated to be valued at USD 55.10 Bn in 2024 and is expected to reach USD 84.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

Life Science Instrumentation Market Key Factors

To learn more about this report, request a free sample copy

With rising investments in research and development of novel drugs, there is an increasing demand for technologically advanced life science instrumentation. Growing initiatives by governments worldwide to promote precision medicine is another factor boosting the adoption of modern life science instrumentation. Pharmaceutical and biotechnology industries are increasingly investing in advanced technologies like machine learning and artificial intelligence to accelerate drug discovery processes. This is creating favorable environment for players in this market with demand for high performance and innovative life science instrumentation expected to rise substantially in the coming years.

Growth in Pharmaceutical R&D Spending and Discovery Research

One of the major drivers fueling the growth of the global life science instrumentation market is the increase in spending on pharmaceutical R&D by biopharmaceutical companies around the world. A number of leading pharmaceutical companies are heavily investing in developing innovative drugs for various therapeutic areas such as oncology, cardiology and immunology. Life science instrumentation tools play a crucial role in enabling discovery research activities by providing accurate analysis, virtual screening and high-throughput testing capabilities. With rising investments dedicated for discovery, these tools have become indispensable for target validation, cell line development, assay optimization and screening large compound libraries to identify potential drug candidates. As per some estimates, the global pharmaceutical R&D expenditure increased from around US$160 billion in 2015 to over US$190 billion in 2020. In the coming years, spending levels are expected to rise further with large players expanding their pipelines and production capacity. Oncology alone accounts for over 25% of the total money invested in R&D activities. Many big pharmaceutical corporations have set aside multi-billion-dollar budgets for research specifically focusing on cancer treatment in a bid to come up with innovative targeted therapies and personalized medicines. This exponential increase in financial allocation for developing breakthrough new drugs will definitely propel the demand for cutting-edge life science instrumentation required by both industry and academic research organizations. For Instance, as indicated in an article from the U.K. Parliament in October 2022, the U.K.'s total expenditure on R&D for the year amounted to EUR 37.1 billion. Additionally, according to OECD data, Bulgaria had the highest pharmaceutical spending as a percentage of GDP in 2021, allocating approximately 32.4% to pharmaceuticals. This increased investment in pharmaceutical R&D is anticipated to drive market expansion in the coming years.

Market Concentration and Competitive Landscape

Life Science Instrumentation Market Concentration By Players

To learn more about this report, request a free sample copy

Growing Adoption of Technological Advancements

Another important factor contributing to the positive outlook of the life science instrumentation market is the rising adoption of new technologies across various application areas. Continuous innovation is taking place in the development of instruments that are more efficient, higher-throughput, miniaturized and capable of multi-modal analysis. Emerging technologies such as automation, machine learning, artificial intelligence, robotics, next-generation sequencing and lab-on-a-chip are tremendously enhancing the capabilities of existing instruments. Transition to automated platforms is helping streamline complex workflow in spaces like proteomics, genomics and cell biology research. Use of robotics is minimizing manual errors and improving reproducibility. Lab automation is drastically reducing processing time and sample volumes required. Life science researchers and companies are rapidly embracing these technological breakthroughs to refine older techniques, develop novel methods and elevate the pace of scientific discovery. Affordable prices of some advanced instruments are also encouraging their wider acceptance. For instance, DNA sequencing machines have become more widespread with advances lowering costs 100 to 1,000-fold compared to previous versions

Key Takeaways of Analyst:

The life science instrumentation market is estimated to see steady growth over the next few years driven by increasing R&D investments in pharmaceutical and biotechnology industries. Advancing proteomics and genomics research will considerably drive the demand for high-throughput screening instruments and spectroscopy technologies. North America dominated the market in the past owing to presence of major players and focus on precision medicine. However, Asia Pacific is projected to be the fastest growing region owing to expanding biopharma industry and large patient pool in China and India.

The increasing prevalence of lifestyle diseases and chronic conditions will augment the need for development of novel therapeutics, thereby stimulating sales of analytical and separation instruments. Industry-academia collaboration in life science research also provides an opportunity to introduce new instrument categories. On the flip side, high costs of advanced life science instrumentation could hamper widespread adoption, especially in price-sensitive developing regions. Intense competition among existing players also limits the scope for extensive profitability. Continued consolidation activities across the life science sector poses a threat to smaller individual instrument manufacturers. Strict regulatory requirements pertaining to approval of new life science instruments also slow down product commercialization. Overall, the life science instrumentation market is expected to witness steady growth over the next decade powered by increasing R&D spending globally.

Market Challenges: High cost of advanced instruments

High cost of advanced life science instruments is one of the major factors restraining the growth of the global life science instrumentation market. The research and development in life science instrumentation requires huge capital investments in advanced technologies. Many benchtops analytical instruments use highly sophisticated technologies like mass spectrometry, spectroscopy, sequencing etc. which pushes the initial costs of these instruments upwards of hundreds of thousands to millions of dollars. Moreover, maintaining precision and accuracy of these instruments over long term requires frequent calibration, validation and upgrade of components which leads to additional operational costs. Several research institutions and academia in developing nations struggle to procure and maintain such expensive instrumentation due to budgetary constraints. As per data from UNESCO Institute for Statistics (UIS), the average expenditure on research and development (R&D) as a percentage of GDP was only 1.7% for low-income countries compared to over 2.4% for high-income countries in 2021. Limited funding for research hampers wider adoption of new life science technologies especially in developing regions of the world. This acts as a barrier for life science companies looking to tap emerging markets.

Market Opportunities: Growing focus on personalized medicine

Growing focus on personalized medicine offers a huge opportunity for the global life science instrumentation market. Personalized medicine takes into account individual variability in genes, environment and lifestyle for each person. It allows doctors or clinicians to select appropriate preventive or therapeutic interventions tailored to the individual. With developments in fields such as pharmacogenomics and molecular diagnostics, it has become possible to analyze an individual's genetic makeup and fine-tune medical treatment based on the person's likely response to drugs or susceptibility to diseases. This shifts the approach from a 'one-size-fits-all' to a tailored treatment for each individual.

Life science instrumentation that can help enable personalized medicine by enabling key aspects such as high-throughput screening, high-sensitivity detection, accurate sample analysis and data processing at the molecular level are poised to grow. For example, next-generation sequencing instruments can rapidly decode whole genomes and detect genetic variations. Such insights allow scientists to better understand how genetic differences influence disease risk, medication response and care management strategies for each person. Mass spectrometry instruments can analyze biological samples to detect protein and metabolite signatures that can serve as biomarkers for diseases or treatment response. Imaging instruments with advanced capabilities help clinicians gain deeper insights into diseases at the molecular level within tissues and cells.

Life Science Instrumentation Market By Technology

To learn more about this report, request a free sample copy

Insights, By Technology: Advancing Genomic Research Boosts PCR Dominance

In terms of Technology, the Polymerase Chain Reaction (PCR) segment is estimated to hold the highest share of 20.12% in 2024 owing to its widespread usage in genomic research and diagnostics. PCR has transformed molecular biology since its invention in 1983, allowing scientists to amplify specific DNA sequences which has powered key advances like genome sequencing. Ever declining costs of PCR instruments and consumables have also boosted their accessibility. Moreover, continuous technical improvements like real-time quantitative PCR and digital PCR have expanded the range of PCR applications. Recently, digital PCR has seen increased adoption for detecting minimal residual diseases and rare mutations as it provides more accurate quantification of nucleic acids without standards. Widespread ability to perform multiplex PCR has augmented its utility in genomic and genetic studies involving large numbers of targets. Further developments towards quantitative PCR for point-of-care pathogen detection would aid its growth prospects. Rising genome research activities aimed at understanding the molecular basis of diseases and developing personalized therapies has sustainably driven the demand for high throughput PCR systems.

Insights, By End User: Pharma R&D Growth Steers Immunoassay Equipment Demand

In terms of End User, the Pharmaceutical and Biotechnology Companies segment is estimated to hold the highest share of 35% in 2024 owing to their substantive investment in R&D requiring advanced life science tools. Immunoassay technology has emerged as an important segment in this regard due to wide applicability in drug development, discovery and production processes. Being a highly sensitive and specific technique, immunoassays are extensively used by pharma companies right from the early stages of drug candidate screening and selection to monitoring drug levels during clinical trials. Areas such as toxicology testing, therapeutic drug monitoring and assessing bio similarity heavily rely on various immunoassay modalities like enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescence immunoassay etc. Complimenting this is the growing need for personalized medicines which has boosted research analyzing genetic and protein biomarkers using immunoassay platforms. Moreover, stringent regulatory norms have increased the pharma industry's dependence on immunoassays for ensuring drug quality, safety and efficacy. Hence, as pharma research expenditures continue escalating globally to offset patent cliff losses, the demand for state-of-the-art immunoassay solutions from leading manufacturers is projected to rise accordingly.

Insights, By Application: Diagnostics Domination Catalyzes Spectroscopy Sales

Among applications, the Clinical & Diagnostic segment is estimated to hold the highest share of 50.10 % in 2024 due to the widespread need for spectroscopic techniques in hospitals and labs. Technologies like absorption spectroscopy (UV-Vis), fluorescence spectroscopy, vibrational spectroscopy (IR and Raman) have become indispensable diagnostic tools. For instance, UV-Vis spectrophotometry finds extensive applications for therapeutic drug monitoring, analyzing hemoglobin levels and screening newborns for metabolic disorders. Similarly, IR spectroscopy enables rapid identification of pathogens and diseases via fingerprinting of biological samples. Fluorescence spectroscopy aids disease diagnosis by detecting the signatures of biomarkers, and allowing imaging of tissues. Rising burden of chronic diseases and increasing insurance coverage has boosted diagnostic testing volumes globally. Further, focus on earlier disease detection and prevention has augmented demand for lab-based diagnostic analyses employing various spectroscopic platforms. Portable instruments capable of point-of-care testing are gaining importance as well owing to benefits like faster diagnosis and treatment. Thus, advancements towards miniaturization and microfluidics-based spectroscopic devices would further catalyze their usage in clinical settings.

Regional Insights

Life Science Instrumentation Market Regional Insights

To learn more about this report, request a free sample copy

North America has long dominated the global life science instrumentation market and is estimated to hold the largest share of 39.2 % in 2024. This can be attributed to the region's heavy investments in biomedical research and presence of top pharmaceutical and biotech companies. The U.S. alone accounts for over 50% of the research spending globally and has the highest healthcare expenditure. Most of the major life science instrumentation OEMs like Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, and Waters Corporation are headquartered in the U.S., giving the region an industry presence edge. North American life science instrumentation also benefits from the localized manufacturing and supply chains of these companies.

The Asia Pacific region has emerged as the fastest growing market for life science instrumentation in recent years. Countries like China, Japan, South Korea, India and others are increasingly investing in healthcare and biomedical infrastructure. This has created a surge in demand for advanced life science research tools and analytical equipment within the region. China remains the major growth driver within Asia Pacific as its pharmaceutical industry expands to fulfill the large healthcare needs of its population. As Chinese pharmaceutical companies develop capabilities in drug discovery and manufacturing, they are procuring more laboratory instruments and automation solutions. Asia Pacific life science instruments also see increased adoption in tandem with rising contract research and manufacturing activities centered in India, Singapore and other Southeast Asian nations. Furthermore, exports of life science instruments from North America and Europe into this region have risen significantly.

Market Report Scope

Life Science Instrumentation Market Report Coverage

Report Coverage Details
Base Year: 2023 Market Size in 2024: US$ 55.10 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 6.2% 2031 Value Projection: US$ 84.11 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Technology: Polymerase Chain Reaction (PCR), Next Generation Sequencing, Immunoassay, Flow Cytometry, Spectroscopy, Electrophoresis, Chromatography, Centrifuges, and Other Technologies
  • By End User: Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Contract Research Organization (CRO), and Academia and Research Institutes
  • By Application: Clinical & Diagnostic, Research, and Others 
Companies covered:

Agilent Technologies, Danaher Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Bruker Corporation, Waters Corporation, GE Healthcare, Shimadzu Corporation, PerkinElmer Inc., Illumina, Inc., Qiagen N.V., Merck KGaA, Abbott Laboratories, Hitachi High-Technologies Corporation, Roche Diagnostics, Beckman Coulter, Inc., and Eppendorf AG

Growth Drivers:
  • Increasing R&D investments in pharmaceutical and biotechnology industries
  • Growing adoption of technological advancements
Restraints & Challenges:
  • High cost of advanced instruments
  • Lack of adequate skills and expertise

Key Developments

  • On April 2024, LICORbio, formerly known as LI-COR Biotechnology, launched two new Odyssey F biomolecular imaging systems. These advanced models promise faster scans, enhanced value, expanded assay support, and maintain the exceptional dynamic range that researchers expect from LICORbio. According to Mike Furtaw, Director of R&D at LICORbio, the Odyssey F represents a significant advancement in their optical imaging technology, offering industry-leading capabilities for speed, versatility in applications, and multiplexing capabilities across both visible and near-infrared spectra.
  • In June 2022, Agilent Technologies introduced new quadrupole mass spectrometers for both liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS), designed to enhance built-in instrument intelligence and provide advanced diagnostic capabilities aimed at maximizing system uptime for customers.
  • In March 2022, Shimadzu, leading-edge science and technology company Europe launched the IRXross Fourier-transform infrared (FTIR) spectrophotometer. This new mid-level FTIR device offers outstanding performance metrics such as a high signal-to-noise ratio, excellent resolution, rapid measurement capabilities, and user-friendly operation.

*Definition: The Global Life Science Instrumentation Market consists of instruments used across various life science industries like biotechnology, pharmaceutical, diagnostic and many more. This includes analytical instruments like chromatography, spectroscopy, PCR and sequencing equipment used for purification, identification and analysis. It also contains lab equipment like centrifuges, incubators, sterilizers used majorly in research activities. The Global Life Science Instrumentation Market aims to advance life science research by providing innovative, high quality and precise analytical tools and lab equipment enabling faster development of drugs, diagnostics and other applications.

Market Segmentation

  •  Technology Insights (Revenue, USD Bn, 2019 - 2031)
    • Polymerase Chain Reaction (PCR)
    • Next Generation Sequencing
    • Immunoassay
    • Flow Cytometry
    • Spectroscopy
    • Electrophoresis
    • Chromatography
    • Centrifuges
    • Other Technologies
  •  End User Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospitals and Diagnostic Centers
    • Pharmaceutical and Biotechnology Companies
    • Contract Research Organization (CRO)
    • Academia and Research Institutes
  •  Application Insights (Revenue, USD Bn, 2019 - 2031)
    • Clinical & Diagnostic
    • Research
    • Others
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Agilent Technologies
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company (BD)
    • Bio-Rad Laboratories, Inc.
    • Bruker Corporation
    • Waters Corporation
    • GE Healthcare
    • Shimadzu Corporation
    • PerkinElmer Inc.
    • Illumina, Inc.
    • Qiagen N.V.
    • Merck KGaA
    • Abbott Laboratories
    • Hitachi High-Technologies Corporation
    • Roche Diagnostics
    • Beckman Coulter, Inc.
    • Eppendorf AG

Frequently Asked Questions

The CAGR of the global life science instrumentation market is projected to be 6.2 from 2024 to 2031.

Increasing R&D investments in pharmaceutical and biotechnology industries and growing adoption of technological advancements are the major factors driving the growth of the global life science instrumentation market.

High cost of advanced instruments and lack of adequate skills and expertise are the major factors hampering the growth of the global life science instrumentation market.

In terms of Technology, Polymerase Chain Reaction (PCR) is estimated to dominate the market revenue share in 2024.

Agilent Technologies, Danaher Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Bruker Corporation, Waters Corporation, GE Healthcare, Shimadzu Corporation, PerkinElmer Inc., Illumina, Inc., Qiagen N.V., Merck KGaA, Abbott Laboratories, Hitachi High-Technologies Corporation, Roche Diagnostics, Beckman Coulter, Inc., Eppendorf AG are the major players.

North America is expected to lead the global life science instrumentation market.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.